Apremilast
Indication
Moderate to severe plaque psoriasis (NICE TA419)
NICE TA419 - Apremilast for treating moderate to severe plaque psoriasis
Red
Brand:
Otezla®
Nice TA:
419
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Skin
Background
Apremilast is recommended as an option for treating chronic plaque psoriasis in adults whose disease has not responded to other systemic therapies, including ciclosporin, methotrexate and PUVA (psoralen and ultraviolet‑A light), or when these treatments are contraindicated or not tolerated, only if:
- the disease is severe, as defined by a total Psoriasis Area Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10
- treatment is stopped if the psoriasis has not responded adequately at 16 weeks; an adequate response is defined as:
- a 75% reduction in the PASI score (PASI 75) from when treatment started or
- a 50% reduction in the PASI score (PASI 50) and a 5‑point reduction in DLQI from start of treatment
- the company provides apremilast with the discount agreed in the patient access scheme. When using the DLQI, healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties, that could affect the responses to the DLQI and make any adjustments they consider appropriate.
Recommendation
LSCMMG Recommendation:
Red
Reason for decision:
Specialist medicine
Supporting documents: